Why the study?
Vericiguat treats HFrEF, but whether it exerts a therapeutic effect on AF and its potential mechanism remained uncertain.
Does vericiguat reduce atrial fibrillation recurrence and myocardial fibrosis in patients with heart failure and paroxysmal AF and in experimental models?
Does vericiguat reduce atrial fibrillation recurrence and myocardial fibrosis in patients with heart failure and paroxysmal AF and in experimental models?
Vericiguat may reduce atrial fibrillation recurrence by alleviating myocardial fibrosis via the TGF-β1/Smad pathway.
No takes yet. Share an insight, caveat, or question.
Supports potential vericiguat benefit in AF-HFrEF; leaves open confirmation in prospective trials.
Sun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: